MDxHealth reported preliminary 2022 revenues and reaffirmed its 2023 revenue guidance. The company expects to report 2022 revenues of approximately $37M, with a year-end cash balance of $15.5M. The company is also reaffirming its previously issued 2023 revenue guidance of $65-$70 million. Michael McGarrity, CEO of mdxhealth, commented: "In 2023, we are focused on operating execution and believe that improved reimbursement, along with our expanded diagnostic product offering will drive growth as reflected in our guidance. With the recent acquisition from Exact Sciences of the Genomic Prostate Score(R) (GPS) test (formerly Oncotype DX GPS), we believe mdxhealth is now a leader in the field of personalized diagnostic solutions focused exclusively on urology, and that our expanded menu will provide our urology customers with a more comprehensive offering of clinically actionable diagnostics to support a clear pathway for patients suspected of or diagnosed with prostate cancer. We are committed to building value for all of our stakeholders including patients, customers and shareholders."
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on MDXH:
